Trials / Completed
CompletedNCT01774032
H5N1 Vaccine Study in Japanese Elderly Population Aged 65 Years and Older
An Open-Label Phase 3 Study to Assess Immunogenicity and Safety of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in a Japanese Elderly Population Aged 65 Years and Older
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 91 (actual)
- Sponsor
- Alachua Government Services, Inc. · Industry
- Sex
- All
- Age
- 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to obtain immunogenicity and safety data of an H5N1 pandemic influenza vaccine in a Japanese elderly population aged 65 years and older.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | H5N1 Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated), non-adjuvanted formulation |
Timeline
- Start date
- 2013-03-01
- Primary completion
- 2013-06-01
- Completion
- 2013-10-01
- First posted
- 2013-01-23
- Last updated
- 2015-10-09
Locations
2 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01774032. Inclusion in this directory is not an endorsement.